Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases

1. A method for the treatment of an inflammatory pulmonary disease comprising administering to a patient in need thereof a pharmaceutical composition comprising a pharmaceutical formulation including

an active ingredient combination consisting of a first amount of a PDE4 inhibitor or a pharmaceutically acceptable salt thereof, and a second amount of a HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof,

and at least one pharmaceutically acceptable auxiliary,

wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, ROFLUMILAST-N-oxide, and pharmaceutically acceptable salts of those compounds,

wherein the HMG-CoA reductase inhibitor is selected from the group consisting of ROSUVASTATIN and pharmaceutically acceptable salts of ROSUVASTATIN, and

wherein the active ingredient combination is present in an effective amount for the treatment of an inflammatory pulmonary disease.

2. A method for the treatment of an inflammatory pulmonary disease comprising administering to a patient in need thereof one or more pharmaceutical formulations jointly including, as active agent components:

(A) a first amount of a PDE4 inhibitor; and

(B) a second amount of a HMG-CoA reductase inhibitor;

wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, ROFLUMILAST-N-oxide, and pharmaceutically acceptable salts of those compounds,

wherein the HMG-CoA reductase inhibitor is selected from the group consisting of ROSUVASTATIN and pharmaceutically acceptable salts of ROSUVASTATIN,

wherein the active agent components consist of the PDE4 inhibitor and the HMG-CoA reductase inhibitor in amounts that jointly are effective for the treatment of an inflammatory pulmonary disease; and

wherein the components (A) and (B) are administered simultaneously, sequentially or separately.

3. The method according to claim 1 , wherein the PDE4 inhibitor is ROFLUMILAST and the HMG-CoA reductase inhibitor is ROSUVASTATIN.

4. The method according to claim 2 , wherein the PDE4 inhibitor is ROFLUMILAST and the HMG-CoA reductase inhibitor is ROSUVASTATIN.

5. The method according to claim 2 , wherein the inflammatory pulmonary disease is selected from the group consisting of asthma, COPD, sclerosis, alveolitis, sarcoidosis, idiopathic pulmonary fibrosis and pulmonary hypertension.

6. The method according to claim 2 , wherein the inflammatory pulmonary disease is COPD.